Boothbay Fund Management
REVB icon

Boothbay Fund Management’s Revelation Biosciences REVB Stock Holding History

Boothbay Fund Management’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Hold
0
– -$4.01M – 2138
2021
Q2 		– Sell
-1
Closed -$14.1M – 172
2021
Q1 		$7.13M Hold
1
– – 0.27% 64
2020
Q4 		$7.11M Buy
+1
New +$14.1M 0.26% 55

Other funds holding REVB

Karpus Investment Management
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Linden Advisors
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Mizuho Securities USA
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
Weiss Asset Management
Weiss Asset Management Boston, Massachusetts $9.5B AUM 55.06% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
W.R. Berkley Corp
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
CVI Holdings
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Boothbay Fund Management's REVB Position: Q3 2021 in Review

Boothbay Fund Management held its Revelation Biosciences (REVB) position steady in Q3 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2138.

Boothbay Fund Management first reported a position in REVB in Q4 2020 and has held it in 2 quarters since. The position peaked at $7.13M in Q1 2021. 1 fund tracked by Wall St. Rank holds REVB as of Q3 2021.

  • Boothbay Fund Management held 0 shares of Revelation Biosciences worth $0 as of Q3 2021.
  • Boothbay Fund Management left its Revelation Biosciences share count unchanged in Q3 2021.
  • Revelation Biosciences made up ﹤0.01% of Boothbay Fund Management's portfolio in Q3 2021, its #2138 holding.
  • Boothbay Fund Management first reported a position in Revelation Biosciences in Q4 2020 and has held it in 2 quarters since.
  • Boothbay Fund Management's Revelation Biosciences position peaked at $7.13M in Q1 2021.
  • 1 fund tracked by Wall St. Rank held Revelation Biosciences as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.